Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs Affecting Neurotransmitter Release or Uptake

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...

Adrenergic Agonists: Indirect-Acting Agents

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse.

Journal of psychopharmacology (Oxford, England)·2009

Same author

Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers.

Journal of psychopharmacology (Oxford, England)·2008

Same author

Development and preliminary experience with an ease of extractability rating system for prescription opioids.

Drug development and industrial pharmacy·2006

Same author

Highly active antiretroviral therapy outcomes in a primary care clinic.

AIDS care·2003

Same author

One-, three-, and six-month outcomes after brief inpatient opioid detoxification.

The American journal of drug and alcohol abuse·2001

Same author

Buprenorphine treatment of pregnant opioid--dependent women: maternal and neonatal outcomes.

Drug and alcohol dependence·2001

Search research articles

Related Experiment Video

Updated: May 25, 2026

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

Published on: July 9, 2016

5-HT3 receptor antagonism and psychoactivity.

J T Sullivan¹, K L Preston, M P Testa

¹Department of Medicine, Johns Hopkins University School of Medicine and Johns Hopkins Bayview Medical Center, Baltimore, MD, USA.

Journal of Psychopharmacology (Oxford, England)

|February 4, 2012

Summary

This summary is machine-generated.

Ondansetron, a 5-HT(3) receptor antagonist, showed no acute psychoactive or rewarding effects in individuals with a history of drug abuse. This study found ondansetron (ondansetron) responses indistinguishable from placebo.

More Related Videos

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

Related Experiment Videos

Last Updated: May 25, 2026

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

Published on: July 9, 2016

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

Area of Science:

Pharmacology
Neuroscience
Psychiatry

Background:

Ondansetron is a clinical anti-emetic.
5-HT(3) receptor antagonism is being explored for psychiatric disorders, including drug abuse.
Understanding ondansetron's psychoactive properties is crucial for its therapeutic potential.

Purpose of the Study:

To evaluate the acute psychoactive and physiological effects of 5-HT(3) receptor antagonism using ondansetron.
To determine if ondansetron produces rewarding effects in individuals with a history of drug abuse.

Main Methods:

A blinded, cross-over study involving eight volunteers with a history of drug abuse.
Intravenous administration of ondansetron (40 mg), cocaine (25 mg) as a positive control, and placebos.
Assessment of subjective and physiological responses.

Main Results:

Ondansetron's effects were indistinguishable from placebo.
Cocaine produced expected subjective and physiological effects.
No acute psychoactive or rewarding effects were observed with ondansetron at the tested dose.

Conclusions:

The prototypic 5-HT(3) receptor antagonist, ondansetron, does not produce acute psychoactive effects at doses up to 40 mg.
Ondansetron does not appear to have rewarding effects under this administration regimen.
Further research may be needed to explore ondansetron's therapeutic utility in psychiatric disorders.